APX001
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Candidemia
Conditions
Candidemia
Trial Timeline
Oct 3, 2018 → Jul 2, 2020
NCT ID
NCT03604705About APX001
APX001 is a phase 2 stage product being developed by Basilea Pharmaceutica for Candidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03604705. Target conditions include Candidemia.
What happened to similar drugs?
4 of 8 similar drugs in Candidemia were approved
Approved (4) Terminated (2) Active (3)
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04148287 | Phase 2 | Completed |
| NCT03604705 | Phase 2 | Completed |
Competing Products
9 competing products in Candidemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| micafungin + Micafungin + Caspofungin | Astellas Pharma | Approved | 43 |
| Micafungin | Astellas Pharma | Approved | 35 |
| AmBisome | Gilead Sciences | Approved | 43 |
| Anidulafungin/Fluconazole | Pfizer | Phase 3 | 32 |
| Anidulafungin + Voriconazole | Pfizer | Approved | 43 |
| Anidulafungin + Fluconazole | Pfizer | Phase 3 | 40 |
| Anidulafungin | Pfizer | Phase 3 | 40 |
| Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + Placebo | Basilea Pharmaceutica | Phase 3 | 41 |
| APX001 | Basilea Pharmaceutica | Phase 2 | 29 |